About Mitchell
Dr. Mitchell Finer serves as a Strategic Advisor for ElevateBio and will focus on supporting the organization as the Company accelerates and expands the first genetic medicines foundry. He is a co-founder of ElevateBio and previously served as the Company’s President of Research & Development and as Chief Executive Officer of Life Edit Therapeutics, ElevateBio’s gene editing business. Additionally, Dr. Finer is an executive partner at MPM Capital.
Dr. Finer led ElevateBio’s R&D efforts, and was instrumental in the scaling of its technologies, expanding of its manufacturing capabilities and capacity, and driving the Company’s growth as a technology-driven organization. Prior to joining ElevateBio, he served as Chief Scientific Officer of bluebird bio, where he led the team that conceived of and developed three approved products: Abecma® for the treatment of multiple myeloma, Zynteglo® for the treatment of beta thalassemia and Skysona® for the treatment of childhood cerebral adrenoleukodystrophy. He has served as founder, executive officer or board member at multiple cell therapy, gene therapy and regenerative medicine companies over the last 33 years, including Adverum Biotechnologies, bluebird bio, Coda Biotherapeutics, Cell Genesys, the Gencell division of Aventis Pharma (now Sanofi), Genteric, Inc., Intracel Corporation, Novacell (now Viacyte, acquired by Vertex), Oncorus, Inc., Semma Therapeutics, Turmeric Acquisition Holdings, and TCR2 Therapeutics.
Education and Accomplishments
Dr. Finer has been named inventor on 15 issued U.S. patents. He completed a post-doctoral fellowship at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. He received his Ph.D. in Biochemistry and Molecular Biology from Harvard University and a B.S. in Biochemistry and Microbiology from the University of California at Berkeley.
